Reference |
Executive Relevance |
|---|---|
| 1. Frank SM, et al. (2024). Greater than sevenfold return on investment for a comprehensive patient blood management program with equivalent or improved outcomes. Anesthesia & Analgesia. | Demonstrates a greater than sevenfold return on investment from comprehensive PBM implementation, driven by reduced transfusions, fewer complications, and improved operational efficiency establishing PBM as a margin-positive enterprise strategy rather than a cost-containment initiative. |
|
2. Warner MA, Ferreira R, Raphael J, Shore-Lesserson L, Grant MC, Hill SS, et al. (2024). Return on investment of preoperative anemia management programs in cardiac surgery: an advisory from the Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Committee with endorsement by the Society for the Advancement of Patient Blood Management. Anesthesia & Analgesia. |
Provides the clearest peer-reviewed evidence that PBM can generate direct clinical revenue through anemia evaluation and treatment while also delivering cost savings and margin expansion, even under conservative reimbursement assumptions. |
| 3. Warner MA, et al. (2021). Implementation of a comprehensive patient blood management program for hospitalized patients at a large United States medical center. Mayo Clinic Proceedings, 96, 2980–2990. | Shows that system-wide PBM implementation at a large and well-respected U.S. institution resulted in sustained reductions in transfusion, complications, and length of stay, validating PBM at scale in real-world operations. |
|
4. Bolliger D, et al. (2025). Outcomes, cost-effectiveness, and ethics in patient blood management. Current Opinion in Anaesthesiology, 38(2), 151–156. |
A concise, contemporary synthesis linking PBM’s clinical outcomes, economic value, and ethical foundations. Well suited for executive-level orientation. |
| 5. Hofmann A, et al. (2022). Patient Blood Management: Improving Outcomes for Millions While Saving Billions. What Is Holding It Up? Anesthesia & Analgesia, 135, 511–523. | High-level synthesis explaining why PBM can save millions per hospital and billions at scale. Details barriers to adoption and system-level opportunities. |
| 6. Hofmann A, et al. (2021). Making patient blood management the new norm(al) as experienced by implementors in diverse countries. BMC Health Services Research, 21, 634. | Demonstrates that PBM delivers consistent clinical and economic benefits across diverse healthcare systems, confirming its adaptability from low-resource to high-resource settings. |
| 7. Meybohm P, et al. (2020). Health economics of Patient Blood Management: a cost-effectiveness analysis. Vox Sanguinis. |
Provides rigorous economic modeling demonstrating PBM’s consistent cost-effectiveness across multiple clinical pathways and implementation scenarios. |
| 8. Franchini M, et al. (2019). Patient blood management: a revolutionary approach to transfusion medicine. Blood Transfusion. | A clear, accessible overview framing PBM as a paradigm shift from product-centered transfusion practice to patient-centered blood management. |
| 9. Roets M, et al. (2025). The cost of downstream adverse outcomes associated with allogeneic transfusion. Healthcare (Basel). | Quantifies the substantial downstream costs of transfusion-related complications (infection, AKI, ICU days, organ dysfunction), reinforcing the financial rationale for PBM beyond blood component acquisition alone. |
| 10. Wu DW, et al. (2024). Impact of PBM on RBC utilization: seven-year retrospective study. Life, 14(2), 232. | Longitudinal U.S. data showing durable reductions in RBC utilization over seven years, supporting PBM as a sustainable, not transient, performance strategy. |
|
11. Salenger R, et al. (2025). Safety of ultra-permissive anemia within a cardiac surgery PBM program. JTCVS Open, 27, 102–109. |
Demonstrates that PBM remains safe and effective even under ultra-restrictive transfusion thresholds in high-risk cardiac surgery populations. |
|
12. World Health Organization (2010). WHA63.12 Resolution on availability, safety, and quality of blood products. World Health Organization (2021). Patient Blood Management Policy Brief: Evidence, Ethics, and Economy. |
Establishes PBM as a globally endorsed health system strategy grounding in evidence, ethics, and economic sustainability. |
| 13. Gombotz H, Hofmann A, Nørgaard A, et al. (2017). Supporting PBM in the EU – Practical Implementation Guide for Hospitals. European Commission. | Provides practical, implementation-focused guidance adopted across multiple European health systems, supporting PBM as an operationally executable strategy. |
| 14. Shander A, et al. (2009). Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion. | Demonstrates that the true cost of an RBC transfusion is three to five times the acquisition price, providing a conservative and defensible foundation for PBM financial analyses. |
| 15. Shander A & Hofmann A. (2010). The cost of blood: multidisciplinary consensus conference for a standard methodology. Transfusion Medicine Reviews, 24, 232–246. | Establishes standardized methodology showing that plasma and platelets carry equal or greater system costs than RBCs, confirming PBM ROI estimates based on RBCs alone are conservative. |
| 16. Ozawa S, et al. (2025). Blood Health: The Ultimate Aim of Patient Blood Management. Anesthesia & Analgesia, 141(5), 950–955. | Establishes Blood Health as the organizing framework of PBM, positioning patient blood optimization as an enterprise-level performance strategy. |
Disclaimer
The Society for the Advancement of Patient Blood Management (SABM) and the educational websites Iron Corner, Coag Corner, and Exec Corner do not provide medical advice. The content of these websites is intended for general informational purposes only and does not address individual circumstances. The information is not intended as a substitute for medical or legal advice, diagnosis or treatment, and its content should not be relied upon to make medical health decisions or for any other medical or legal purposes. Readers should never ignore medical advice in seeking treatment because of something they have read in the SABM website, Iron Corner, Coag Corner, or Exec Corner. Readers should make their own determinations as to: (i) what constitutes appropriate medical, technical, and administrative practices, and (ii) how best to evaluate and utilize for medical purposes any content posted in the SABM website, Iron Corner, Coag Corner, or Exec Corner educational resources and (iii) how best to comply with laws and regulations relevant to any questions. For the latter, readers should consider consulting, as to any medical matters, a qualified physician, and, as to any legal matters, an attorney familiar with related state and federal laws. The user of the SABM website, Iron Corner, Coag Corner, or Exec Corner, by accessing same, assumes all risks arising out of such use and releases SABM and its respective members, directors, officers and agents from and against any loss, damage, claim or liability arising out of such use of the SABM website, Iron Corner, Coag Corner, or Exec Corner. The SABM, Iron Corner, Coag Corner, and Exec Corner websites are based in the United States and the content herein as based on information (including, for instance, information and data pertaining to lab indices, pharmaceutical products and treatment protocols) pertaining to the United States for users in the United States. Additionally, information in this website pertaining to typical private and government insurance reimbursement issues may vary from one region of the United States to another. This site also contains “off label” information. Users of this website should be guided accordingly.